A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML.
Gopal S, Lu Q, Man JJ, Baur W, Rao SP, Litichevskiy L, Papanastasiou M, Creech AL, DeRuff KC, Mullahoo J, Officer A, Egri SB, Davison D, Jaffe JD, Jaffe IZ.
Gopal S, et al. Among authors: lu q.
Blood Adv. 2018 Jul 24;2(14):1680-1684. doi: 10.1182/bloodadvances.2018020396.
Blood Adv. 2018.
PMID: 30021779
Free PMC article.